Forte Biosciences (FBRX) Change in Account Payables (2016 - 2026)
Forte Biosciences (FBRX) reported Change in Account Payables of $3.1 million for Q1 2026, up 435.47% year-over-year from $578000.0 in Q1 2025, and down 31.18% quarter-over-quarter from $4.5 million in Q4 2025.
Forte Biosciences (FBRX) Change in Account Payables (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 11 years of Change in Account Payables data on file, last reported at $3.1 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $3.1 million, up 435.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.1 million (up 141.46% YoY), and the FY2025 annual result was $5.5 million, up 83.48% from the prior year.
- Change in Account Payables fell to $3.1 million in Q1 2026 per FBRX's latest filing, from $4.5 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $4.5 million in Q4 2025 and troughed at -$3.9 million in Q4 2023.
- A 5-year average of $713941.2 and a median of $261000.0 in 2024 frame the typical range for Change in Account Payables.
- On a YoY basis, Change in Account Payables climbed as much as 1689.25% in 2023 and fell as far as 21577.78% in 2023.
- A 5-year view of Change in Account Payables shows it stood at $18000.0 in 2022, then plunged by 21577.78% to -$3.9 million in 2023, then soared by 81.53% to -$714000.0 in 2024, then surged by 729.83% to $4.5 million in 2025, then slumped by 31.18% to $3.1 million in 2026.
- Business Quant data shows FBRX's Change in Account Payables at $3.1 million in Q1 2026, $4.5 million in Q4 2025, and $558000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | 3.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.10 Mn |
| Mar 31, 2026 | 3.10 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 558,000.00 |
| Sep 30, 2025 | 558,000.00 |
| Jun 30, 2025 | -90,000.00 |
| Jun 30, 2025 | -90,000.00 |
| Mar 31, 2025 | 578,000.00 |
| Mar 31, 2025 | 578,000.00 |
| Dec 31, 2024 | -714,000.00 |
| Dec 31, 2024 | -714,000.00 |
| Sep 30, 2024 | -116,000.00 |
| Sep 30, 2024 | -116,000.00 |
| Jun 30, 2024 | 3.59 Mn |
| Jun 30, 2024 | 3.59 Mn |
| Mar 31, 2024 | 261,000.00 |
| Mar 31, 2024 | 261,000.00 |
| Dec 31, 2023 | -3.87 Mn |
| Dec 31, 2023 | -3.87 Mn |